Management of high-risk prostate cancer: Radiation therapy and hormonal therapy

Cancer Treatment Reviews

Volumn 39, Issue 8, 2013, Pages 872-878

  Nomiya, Takuma ^a   Tsuji, Hiroshi ^a   Toyama, Shingo ^a   Maruyama, Katsuya ^a   Nemoto, Kenji ^b   Tsujii, Hirohiko ^a   Kamada, Tadashi ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b YAMAGATA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Androgen antagonists; Clinical trial; Prostatic neoplasms; Radiotherapy; Review

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BIOCHEMICAL RECURRENCE FREE SURVIVAL; BRACHYTHERAPY; CANCER CONTROL; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; GASTROINTESTINAL HEMORRHAGE; GLEASON SCORE; HIGH RISK PATIENT; HIGH RISK POPULATION; HIGH RISK PROSTATE CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; LONG TERM CARE; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; PROSTATE CANCER; PROSTATECTOMY; PROTON THERAPY; RADIATION DOSE; RADIATION INJURY; RELATIVE BIOLOGIC EFFECTIVENESS; REVIEW; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

ANDROGEN ANTAGONISTS; CLINICAL TRIAL; PROSTATIC NEOPLASMS; RADIOTHERAPY; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BRACHYTHERAPY; CHEMORADIOTHERAPY; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTON THERAPY;

EID: 84883561284     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.04.003     Document Type: Review

References (48)

1. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280(11):969-974.
2. NCCN Clinical Practice Guidelines in Oncology. Prostate cancer. version 4.2011. National comprehensive cancer network guidelines. http://www.nccn.org/.
3. Consensus Statement Guidelines for PSA following radiation therapy. American society for therapeutic radiology and oncology consensus panel. Int J Radiat Oncol Biol Phys 1997, 37(5):1035-1041.
4. Roach M., Hanks G., Thames H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65(4):965-974.
5. Pilepich M.V., Krall J.M., Johnson R.J., et al. Extended field (periaortic) irradiation in carcinoma of the prostate - analysis of RTOG 75-06. Int J Radiat Oncol Biol Phys 1986, 12(3):345-351.
6. Asbell S.O., Krall J.M., Pilepich M.V., et al. Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06. Int J Radiat Oncol Biol Phys 1988, 15(6):1307-1316.
7. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. Prostate-specific antigen for pretreatment prediction and posttreatment evaluation of outcome after definitive irradiation for prostate cancer. Int J Radiat Oncol Biol Phys 1995, 32(2):307-316.
8. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53(5):1097-1105.
9. Zelefsky M.J., Yamada Y., Fuks Z., et al. Long-term results of conformal radiotherapy for prostate cancer: impact of dose escalation on biochemical tumor control and distant metastases-free survival outcomes. Int J Radiat Oncol Biol Phys 2008, 71(4):1028-1033.
10. Michalski J., Bhandari M., Gupta N., et al. Clinical outcome of patients treated with 3D conformal radiation therapy (3D-CRT) for prostate cancer on RTOG 9406. Int J Radiat Oncol Biol Phys 2012, 83(3):e363-e370.
11. Cahlon O., Zelefsky M.J., Shippy A., et al. Ultra-high dose (86.4Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008, 71(2):330-337.
12. Engels B., Soete G., Verellen D., Storme G. Conformal arc radiotherapy for prostate cancer: increased biochemical failure in patients with distended rectum on the planning computed tomogram despite image guidance by implanted markers. Int J Radiat Oncol Biol Phys 2009, 74(2):388-391.
13. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993, 150(1):110-114.
14. Masson S., Persad R., Bahl A. HDR brachytherapy in the management of high-risk prostate cancer. Adv Urol 2012, 2012:980841. Epub 2012 Feb 22. 10.1155/2012/980841.
15. Galalae R.M., Martinez A., Mate T., et al. Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58(4):1048-1055.
16. Demanes D.J., Rodriguez R.R., Schour L., Brandt D., Altieri G. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results. Int J Radiat Oncol Biol Phys 2005, 61(5):1306-1316.
17. Aström L., Pedersen D., Mercke C., Holmäng S., Johansson K.A. Long-term outcome of high dose rate brachytherapy in radiotherapy of localised prostate cancer. Radiother Oncol 2005, 74(2):157-161.
18. Hoskin P.J., Motohashi K., Bownes P., Bryant L., Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol 2007, 84(2):114-120.
19. Nag S., Beyer D., Friedland J., Grimm P., Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys 1999, 44(4):789-799.
20. Prada P.J., Juan G., González-Suárez H., et al. Prostate-specific antigen relapse-free survival and side-effects in 734 patients with up to 10years of follow-up with localized prostate cancer treated by permanent iodine implants. BJU Int 2010, 106(1):32-36.
21. Rivard M.J., Butler W.M., Devlin P.M., et al. American Brachytherapy Society recommends no change for prostate permanent implant dose prescriptions using iodine-125 or palladium-103. Brachytherapy 2007, 6(1):34-37.
22. Fang L.C., Merrick G.S., Butler W.M., et al. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15ng/mL treated with permanent interstitial brachytherapy. Int J Radiat Oncol Biol Phys 2011, 81(4):992-996.
23. Shipley W.U., Verhey L.J., Munzenrider J.E., et al. Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 1995, 32(1):3-12.
24. Slater J.D., Rossi C.J., Yonemoto L.T., et al. Proton therapy for prostate cancer: the initial Loma Linda University experience. Int J Radiat Oncol Biol Phys 2004, 59(2):348-352.
25. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2008, 299(8):899-900. Erratum in: JAMA. 2008; 299(8): 899-900.
26. Yashkin P.N., Silin D.I., Zolotov V.A., et al. Relative biological effectiveness of proton medical beam at Moscow synchrotron determined by the Chinese hamster cells assay. Int J Radiat Oncol Biol Phys 1995, 31(3):535-540.
27. Coen J.J., Bae K., Zietman A.L., et al. Acute and late toxicity after dose escalation to 82GyE using conformal proton radiation for localized prostate cancer: initial report of American College of Radiology Phase II study 03-12. Int J Radiat Oncol Biol Phys 2011, 81(4):1005-1009.
28. Tobias C.A., Blakely E.A., Alpen E.L., et al. Molecular and cellular radiobiology of heavy ions. Int J Radiat Oncol Biol Phys 1982, 8(12):2109-2120.
29. Suzuki M., Kase Y., Yamaguchi H., Kanai T., Ando K. Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with heavy-ion medical accelerator in Chiba (HIMAC) carbon-ion beams. Int J Radiat Oncol Biol Phys 2000, 48(1):241-250.
30. Akakura K., Tsujii H., Morita S., et al. Working Group for Genitourinary Tumors, National Institute of Radiological Science. Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 2004, 58(3):252-258.
31. Tsuji H., Yanagi T., Ishikawa H., et al. Working Group for Genitourinary Tumors. Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int J Radiat Oncol Biol Phys 2005, 63(4):1153-1160.
32. Ishikawa H., Tsuji H., Kamada T., et al. Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study. Radiother Oncol 2006, 81(1):57-64.
33. Okada T., Tsuji H., Kamada T., et al. Carbon ion radiotherapy in advanced hypofractionated regimens for prostate cancer: from 20 to 16 fractions. Int J Radiat Oncol Biol Phys 2012, 84(4):968-972.
34. Duncan W., Warde P., Catton C.N., et al. Carcinoma of the prostate: results of radical radiotherapy (1970-1985). Int J Radiat Oncol Biol Phys 1993, 26(2):203-210.
35. Pilepich M.V., Krall J., George F.W., et al. Treatment-related morbidity in phase III RTOG studies of extended-field irradiation for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1984, 10(10):1861-1867.
36. Vargas C., Martinez A., Kestin L.L., et al. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy. Int J Radiat Oncol Biol Phys 2005, 62(5):1297-1308.
37. Zelefsky M.J., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166(3):876-881.
38. Masson S., Persad R., Bahl A. HDR brachytherapy in the management of high-risk prostate cancer. Adv Urol 2012, 2012:980841. Epub 2012 Feb 22. 10.1155/2012/980841.
39. Ishikawa H., Tsuji H., Kamada T., et al. Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66(4):1084-1091.
40. Pilepich M.V., Buzydlowski J.W., John M.J., et al. Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate: outcome results of RTOG 83-07. Int J Radiat Oncol Biol Phys 1995, 32(1):175-180.
41. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 1997, 15(3):1013-1021.
42. Pilepich M.V., Winter K., John M.J., et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001, 50(5):1243-1252.
43. Bolla M., Collette L., Blank L., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360(9327):103-106.
44. Hanks G.E., Pajak T.F., Porter A., et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003, 21(21):3972-3978.
45. Bolla M., Van Tienhoven G., Warde P., et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010, 11(11):1066-1073.
46. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31. J Clin Oncol 2009, 27(1):92-99.
47. Efstathiou J.A., Bae K., Shipley W.U., et al. Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02. Eur Urol 2008, 54(4):816-823.
48. Lawton C.A., Bae K., Pilepich M., et al. Long-term treatment sequelae after external beam irradiation with or without hormonal manipulation for adenocarcinoma of the prostate: analysis of radiation therapy oncology group studies 85-31, 86-10, and 92-02. Int J Radiat Oncol Biol Phys 2008, 70(2):437-441.